HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies.


Journal

Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 03 05 2019
accepted: 29 10 2019
pubmed: 11 11 2019
medline: 4 9 2020
entrez: 10 11 2019
Statut: ppublish

Résumé

Targeted therapies have resulted in major advances in the treatment of HER2-positive breast cancers. Despite this, up to 70% of patients will develop resistance to treatment within 2 years and new strategies for targeting resistant disease are needed. To identify potential resistance mechanisms, we used the mouse MMTV-NIC-PTEN Treatment of tumor-bearing MMTV-NIC-PTEN Together these data indicate a role for HO-1-induced autophagy in resistance to pan-HER family kinase inhibitors.

Identifiants

pubmed: 31705351
doi: 10.1007/s10549-019-05489-1
pii: 10.1007/s10549-019-05489-1
pmc: PMC6997276
doi:

Substances chimiques

AZD 8931 0
Antineoplastic Agents 0
Membrane Proteins 0
Protein Kinase Inhibitors 0
Quinazolines 0
Lapatinib 0VUA21238F
Heme Oxygenase-1 EC 1.14.14.18
Hmox1 protein, mouse EC 1.14.14.18
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

543-555

Subventions

Organisme : Cancer Research UK
ID : C157/A15703
Pays : United Kingdom

Références

Vascul Pharmacol. 2015 Nov;74:11-22
pubmed: 26392237
Dis Model Mech. 2016 Feb;9(2):131-40
pubmed: 26721874
Biomed Pharmacother. 2016 Mar;78:30-38
pubmed: 26898422
Dis Model Mech. 2017 Apr 1;10(4):359-371
pubmed: 28381598
Breast Care (Basel). 2013 Mar;8(1):49-55
pubmed: 24715843
Oncogene. 2002 Sep 12;21(41):6255-63
pubmed: 12214266
Breast Care (Basel). 2013 May;8(2):149-54
pubmed: 24415964
Clin Cancer Res. 2005 May 15;11(10):3790-8
pubmed: 15897578
J Biomed Sci. 2015 Mar 21;22:22
pubmed: 25885228
Cancer Cell. 2004 Aug;6(2):117-27
pubmed: 15324695
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Oxid Med Cell Longev. 2016;2016:1958174
pubmed: 26697129
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1502-13
pubmed: 24817946
J Invest Dermatol. 2009 Nov;129(11):2594-603
pubmed: 19536150
FEBS Lett. 2014 Jan 3;588(1):79-85
pubmed: 24269680
EMBO J. 2008 Mar 19;27(6):910-20
pubmed: 18273058
Genes Dev. 2016 Sep 1;30(17):1913-30
pubmed: 27664235
Apoptosis. 2016 Apr;21(4):489-501
pubmed: 26801320
IUBMB Life. 2012 May;64(5):362-9
pubmed: 22431005
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Oncogene. 2015 Apr 30;34(18):2360-70
pubmed: 24931165
Front Oncol. 2012 Jun 18;2:62
pubmed: 22720269
Cell Prolif. 2016 Feb;49(1):90-101
pubmed: 26726846
Oncol Lett. 2012 Dec;4(6):1247-1253
pubmed: 23205122
Oncotarget. 2016 May 17;7(20):28868-80
pubmed: 26930712
Int J Mol Med. 2017 Nov;40(5):1537-1548
pubmed: 28901391
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Int J Mol Sci. 2017 Jun 16;18(6):
pubmed: 28621712
Oncogene. 2006 Jun 8;25(24):3365-74
pubmed: 16462769
J Biol Chem. 2014 Sep 26;289(39):26882-94
pubmed: 25107906
Cancer Res. 2004 Jun 1;64(11):3958-65
pubmed: 15173008
Eur J Med Chem. 2019 Apr 1;167:439-453
pubmed: 30784878
Hepatology. 2011 Jun;53(6):2053-62
pubmed: 21437926
ACS Med Chem Lett. 2013 May 31;4(8):742-6
pubmed: 24900741
J Pathol. 2013 Aug;230(4):430-40
pubmed: 23616343
Arch Dermatol Res. 2012 Jul;304(5):387-95
pubmed: 22310733
Biochim Biophys Acta. 2014 Apr;1842(4):613-22
pubmed: 24380881
BMC Cancer. 2014 Jun 14;14:436
pubmed: 24927633
Nature. 2013 Sep 19;501(7467):355-64
pubmed: 24048068
Cancer Res. 2016 Sep 15;76(18):5192-4
pubmed: 27635041
J Cell Mol Med. 2018 Nov;22(11):5311-5321
pubmed: 30216645
J Biol Chem. 2007 Jul 13;282(28):20621-33
pubmed: 17430897
Nat Rev Clin Oncol. 2011 Nov 29;9(1):16-32
pubmed: 22124364
Cell Death Dis. 2013 Oct 10;4:e838
pubmed: 24113172
Sci Rep. 2014 Dec 03;4:7201
pubmed: 25467193
Cancer Sci. 2015 Aug;106(8):1023-32
pubmed: 26041409
Blood. 2008 Feb 15;111(4):2200-10
pubmed: 18024796
Cancer Treat Rev. 2018 Jun;67:10-20
pubmed: 29751334
Curr Cancer Drug Targets. 2014;14(4):337-47
pubmed: 24655000
Antioxid Redox Signal. 2014 Apr 10;20(11):1723-42
pubmed: 24180287

Auteurs

Natasha Tracey (N)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Helen Creedon (H)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Alain J Kemp (AJ)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Jayne Culley (J)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Morwenna Muir (M)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.

Teresa Klinowska (T)

Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, UK.

Valerie G Brunton (VG)

Edinburgh Cancer Research UK Centre, Institute of Genetics & Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK. v.brunton@ed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH